A Pilot Study of Lenalidomide Alternating With Ipilimumab Post Allogeneic and Autologous Stem Cell Transplantation

Trial Profile

A Pilot Study of Lenalidomide Alternating With Ipilimumab Post Allogeneic and Autologous Stem Cell Transplantation

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 14 Dec 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Lenalidomide (Primary)
  • Indications B cell lymphoma; Diffuse large B cell lymphoma; Haematological malignancies; Mantle-cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Dec 2017 Planned number of patients changed from 30 to 40.
    • 08 Dec 2017 Planned End Date changed from 1 Nov 2018 to 1 Nov 2019.
    • 08 Dec 2017 Planned primary completion date changed from 1 Nov 2018 to 1 Nov 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top